Biolight announced the termination of its planned control change, and trading in the company's shares and convertible bonds will resume from the market open on August 10. During the suspension, the controlling shareholder and the counterparty fully discussed the relevant major matters, but due to the many issues involved, all parties decided to terminate the plan after careful consideration. Previously, the company's actual controller Yan Jinyuan and concert party Wang Shi had agreed to transfer a 7% stake to Quwei Zhihe in January this year, with a total transaction value of approximately 175 million yuan. After the transfer, the two together hold 22.18% of the shares. Biolight has reported losses for three consecutive years, with net profit attributable to the parent company of minus 65.19 million yuan in 2023, minus 71.44 million yuan in 2024, and minus 69.43 million yuan in 2025. In the first quarter of this year, it continued to lose 7.32 million yuan. The company also recently adjusted its 2022 private placement fundraising projects, and it is expected that the remaining raised funds of approximately 60.66 million yuan will be permanently used to supplement working capital.
Guangdong Biolight Meditech Co LtdTermination of control change plan and continued losses
